Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trialYi‐Long Wu, Tae Min Kim, Valentina Guarneri et al.|The Lancet Oncology|2024Cited by 98
Early childhood asthma: What are the questions?M Silverman, Søren Pedersen, Lynn M. Taussig et al.|American Journal of Respiratory and Critical Care Medicine|1995Cited by 11
Post-discharge spirometry evaluation in patients recovering from moderate-to-critical COVID-19: a cross-sectional studyChee-Shee Chai, Mohammed Fauzi Bin Abdul Rani, Busra Binti Johari et al.|Scientific Reports|2024Cited by 6
Post-Discharge Spirometry Evaluation in Patients Recovering from Moderate-to-Critical COVID-19: A Prospective Cohort StudyChee-Shee Chai, Mohammed Fauzi Bin Abdul Rani, Muhammad Amin Ibrahim et al.|Research Square|2024Cited by 0